September 24, 2017 2:47 PM ET


Company Overview of Chimerix, Inc.

Company Overview

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat ...

2505 Meridian Parkway

Suite 100

Durham, NC 27713

United States

Founded in 2000

87 Employees





Key Executives for Chimerix, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $523.4K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Age: 59
Total Annual Compensation: $359.1K
Chief Medical Officer
Age: 48
Total Annual Compensation: $412.7K
Chief Strategy and Commercial Officer
Age: 53
Total Annual Compensation: $367.5K
Compensation as of Fiscal Year 2016.

Chimerix, Inc. Key Developments

Chimerix, Inc. Appoints Heather Knight-Trent as Vice President of Regulatory Affairs

Chimerix, Inc. announced the appointment of Heather Knight-Trent, PharmD, as vice president of regulatory affairs. Dr. Knight-Trent brings more than 15 years of pharmaceutical regulatory experience to the company and will be responsible for managing all U.S. and global regulatory matters for the company, including strategy, filings and interactions with regulatory authorities. Dr. Knight-Trent was previously executive director of regulatory affairs at Hurley Consulting Associates, where she was responsible for regulatory strategy and implementation for multiple clients. She was previously at Bristol Myers Squibb for ten years in roles both in the U.S. and Europe, most recently as the director of global regulatory, safety and biometrics business operations. In this role Dr. Knight-Trent supported the vice presidents of global regulatory strategy for all therapeutic areas on resourcing, budget, group capabilities and continuous improvement projects.

Chimerix, Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2017

Chimerix, Inc. reported unaudited consolidated earnings results for second quarter and six months ended June 30, 2017. For the quarter, the company’s contract revenue was $675,000 against $1,841,000 a year ago. Loss from operations was $17,245,000 against $18,525,000 a year ago. Net loss was $16,680,000 against $18,148,000 a year ago. Net loss, basic and diluted per share was $0.36 against $0.39 a year ago. For the six months, the company’s contract revenue was $1,753,000 against $3,069,000 a year ago. Loss from operations was $35,505,000 against $45,157,000 a year ago. Net loss was $34,434,000 against $44,408,000 a year ago. Net loss, basic and diluted per share was $0.74 against $0.96 a year ago.

Chimerix, Inc., Q2 2017 Earnings Call, Aug 07, 2017

Chimerix, Inc., Q2 2017 Earnings Call, Aug 07, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Chimerix, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at